HELP Share Price Performance
US$5.22
-1.58 (-23.24%)
94.4% undervalued intrinsic discount
US$92.85
Fair Value
Price US$5.22
AnalystHighTarget US$92.85
AnalystConsensusTarget US$49.46
BrightSide
Fair ValueUS$92.85
Share Pricen/a
Cybin Inc. Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 57 Fair Values set on narratives written by author
HELP Community Narratives
AN
Fair Value US$92.85 94.4% undervalued intrinsic discount
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$49.46 89.4% undervalued intrinsic discount
Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
BR
Fair Value US$0 n/aintrinsic discount
Cybin will leverage its 70 patents for breakthroughs in holistic depression treatment
1users have liked this narrative
1users have commented on this narrative
8users have followed this narrative
Cybin will leverage its 70 patents for breakthroughs in holistic depression treatment
1. Cybin's Intellectual Property : Cybin has over 70 granted patents and 220 patent applications pending across multiple patent families.Read more
252
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
8users have followed this narrative
BR
US$0
n/aintrinsic discount
Fair Value
Profit Margin
14.75%
Future PE
22.08x
Price in 2030
US$0
Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Read more
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$22.14
76.4% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
1.66kx
Price in 2029
US$0
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Read more
41
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$92.85
94.4% undervalued intrinsic discount
Fair Value
Profit Margin
20.06%
Future PE
203.03x
Price in 2029
US$0
Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Read more
116
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$49.46
89.4% undervalued intrinsic discount
Fair Value
Profit Margin
21.47%
Future PE
98.85x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
BR
Cybin will leverage its 70 patents for breakthroughs in holistic depression treatment
Fair Value: US$0 0% overvalued intrinsic discount
8 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Fair Value: US$22.14 76.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Fair Value: US$92.85 94.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cybin Inc. Key Details
About HELP
- Founded
- n/a
- Employees
- 50
- CEO
- WebsiteView website
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Recent HELP News & Updates
